A Myelofibrosis Master Class
Dr.Jason Gotlib, a Stanford School of Medicine hematologist, is one of the new generation of researchers and clinical investigators, specifically trained in clinical investigation. He has specialized in the myeloproliferative neoplasms and myelodysplastic syndromes. Beyond his clinical practice, he was principal investigator on ruxolitinib at Stanford and is prinicipal investigator in the on-going trials of the YMBiosciences’ JAK inhibitor, CYT387.
When we first saw his PowerPoint presentation on JAK inhibitors in myelofibrosis delivered at the MPN Foundation Symposium, we realized it was a master class for patients, caregivers and physicians. Dr. Gotlib offered a comprehensive overview of symptoms, treatment options, the JAK inhibition mechanism, and results from several clinical studies.
How to view the presentation: We converted the PowerPoint format into a full-size slide set you can control. With the cursor hovering over the lower part of each side, you can freeze and study the slide, go back to review or forward to the conclusion.
The MPN Research Foundation Symposium
The MPN Research Foundation hosted a patient education symposium last month in San Mateo, California. Here are the slides accompanying presentations by Drs. Ruben Mesa, Ross Levine, Jason Gotlib and Laura Michaelis
|Ross Levine, MD||Genetics of MPNs – insights from genomic and functional studies|
|Jason Gotlib, MD, MS||JAK Inhibitors in Myelofibrosis: What We Know and Don’t Know|
|Ruben Mesa, MD||Overcoming your MPN!
|Laura Michaelis, MD||Unique Challenges in MPNs (Gender and MPN)|
© MPNforum.com, 2012. Unauthorized use and/or duplication of this material without express and written permission from this blog’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to MPNforum.com with appropriate and specific direction to the original content.